The pharmaceutical industry is constantly evolving and
although billions of pounds are spent yearly developing new drugs and medical
devices, innovation in the field of dermatology is one area that has lacked
investment for a number of years.
From my humble beginnings as a sales rep, selling the
first form of liquid Gaviscon, to board level positions in multi million pound
pharmaceutical companies, I have seen almost everything the industry has to offer.
In many people’s eyes the first major development in the
treatment of skin conditions was the introduction of Topical steroids in the
1950’s. These revolutionised the
treatment of eczema and inflammatory skin conditions generally. For decades the
indication “steroid responsive dermatosis” gives a clue as to how specific a
diagnosis had to be when choosing appropriate drug treatment for widely varying
skin diseases!
There then followed a gap of almost 40 years before the
next class of topical eczema treatments were introduced into clinical practice.
Tacrolimus and pimecrolimus (topical immunomodulators, TIM’s) were launched in
the 1990’s at a time when fears over the potential side effects of topical
steroids were reaching fever pitch. Subsequent safety warnings from regulators
seriously limited the usage of TIM’s through the 2000’s.
Apart from techniques such as wet-wrapping (now declining
in popularity) nothing significant has happened in the last 20 years and it
looks as though nothing significant is going to happen for the next 20 – unless
research into filaggrin bears fruit.
A review by Massimo Riccaboni of the University of Trento
and published by the Office of Health Economics (OHE Seminar Briefing No 11
June 2012) makes depressing reading for sufferers of skin diseases.
Dermatology accounts for 3% of worldwide pharmaceutical
industry R&D spend and is declining, whereas research into new anti-cancer
agents makes up 30% of investment and is growing at 8%. Yet the probability of
success (measured by regulatory approval) is 7% in dermatology and 2% with
anti-cancer programmes.
We believe that it is companies such as ours that can
truly innovate and develop a unique product such as DreamSkin that eczema
patients will rely on for years to come.
Eczema affects up to 10% of the UK population, 20%-25% of
children and is increasing. 15% of all
visits to a GP include skin complaint as the reason for the consultation, with
eczema being by far the most common reason.
About
Dreamskin
DreamSkin polymer coated silk clothing is changing the
way eczema is treated. The polymer moisturises the skin, protects against
common irritants such as washing powder residues, pollen and dust and helps to
regulate body temperature.
DreamSkin is available on prescription
By Tony Wilson
By Tony Wilson